JP2021512904A5 - - Google Patents
Info
- Publication number
- JP2021512904A5 JP2021512904A5 JP2020542613A JP2020542613A JP2021512904A5 JP 2021512904 A5 JP2021512904 A5 JP 2021512904A5 JP 2020542613 A JP2020542613 A JP 2020542613A JP 2020542613 A JP2020542613 A JP 2020542613A JP 2021512904 A5 JP2021512904 A5 JP 2021512904A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- composition according
- patient
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627408P | 2018-02-07 | 2018-02-07 | |
| US62/627,408 | 2018-02-07 | ||
| US201862694318P | 2018-07-05 | 2018-07-05 | |
| US62/694,318 | 2018-07-05 | ||
| US201862772956P | 2018-11-29 | 2018-11-29 | |
| US62/772,956 | 2018-11-29 | ||
| PCT/US2019/016844 WO2019157050A1 (en) | 2018-02-07 | 2019-02-06 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512904A JP2021512904A (ja) | 2021-05-20 |
| JP2021512904A5 true JP2021512904A5 (enExample) | 2022-02-16 |
Family
ID=67540670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542613A Pending JP2021512904A (ja) | 2018-02-07 | 2019-02-06 | Ａｎｃａ関連血管炎の治療のためのある種の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニル］−１，４−オキサゼパン−２−カルボキサミド |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20190247400A1 (enExample) |
| EP (1) | EP3749326A4 (enExample) |
| JP (1) | JP2021512904A (enExample) |
| KR (1) | KR20200118103A (enExample) |
| AU (1) | AU2019217870A1 (enExample) |
| CA (1) | CA3089240A1 (enExample) |
| WO (1) | WO2019157050A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| HUE070049T2 (hu) | 2018-03-01 | 2025-05-28 | Astrazeneca Ab | (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények |
| WO2020018547A1 (en) * | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| US20210252015A1 (en) * | 2018-07-17 | 2021-08-19 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease |
| EP4182700A4 (en) | 2020-07-20 | 2024-11-13 | Insmed Incorporated | METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATMENT OF DIPETIDYL PEPTIDASE-1-MEDIATED DISEASES |
| CN115996923B (zh) * | 2020-08-26 | 2025-07-18 | 海思科医药集团股份有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| US20240150335A1 (en) * | 2021-02-05 | 2024-05-09 | Medshine Discovery Inc. | Fused ring derivatives containing 1,4-oxazepane |
| EP4450497A4 (en) * | 2022-01-11 | 2025-11-26 | Shanghai Yidian Pharmaceutical Tech Development Co Ltd | NITRILE PEPTIDYL COMPOUND AND ITS USES |
| EP4479059A4 (en) * | 2022-02-16 | 2026-01-28 | Insmed Inc | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE |
| AU2023296161A1 (en) | 2022-06-13 | 2025-01-02 | Alivexis, Inc. | Azacycloalkyl carbonyl cyclic amine compound |
| JP2026503035A (ja) | 2023-01-06 | 2026-01-27 | インスメッド インコーポレイテッド | 新規な可逆性ｄｐｐ１阻害剤及びその用途 |
| JP2026507449A (ja) * | 2023-02-15 | 2026-03-04 | インスメッド インコーポレイテッド | Ｄｐｐ１阻害剤としてのある特定の１，４－オキサゼパン－２－カルボキサミドの使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0516297A (pt) * | 2004-10-05 | 2008-09-02 | Genentech Inc | métodos de tratamento de vasculite e artigos de fabricação |
| CN104114557B (zh) * | 2012-02-21 | 2017-10-24 | 默克专利股份公司 | 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪 |
| WO2014091443A1 (en) * | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| JP6437929B2 (ja) * | 2013-03-14 | 2018-12-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| NO2699580T3 (enExample) * | 2014-01-24 | 2018-02-24 | ||
| JP6529575B2 (ja) * | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
| EP3511331A1 (en) * | 2014-09-12 | 2019-07-17 | Boehringer Ingelheim International GmbH | Spirocyclic inhibitors of cathepsin c |
| KR20240091302A (ko) * | 2016-07-29 | 2024-06-21 | 인스메드 인코포레이티드 | 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 |
-
2019
- 2019-02-06 CA CA3089240A patent/CA3089240A1/en active Pending
- 2019-02-06 EP EP19751012.6A patent/EP3749326A4/en not_active Withdrawn
- 2019-02-06 US US16/269,191 patent/US20190247400A1/en not_active Abandoned
- 2019-02-06 JP JP2020542613A patent/JP2021512904A/ja active Pending
- 2019-02-06 US US16/968,381 patent/US20200390781A1/en not_active Abandoned
- 2019-02-06 WO PCT/US2019/016844 patent/WO2019157050A1/en not_active Ceased
- 2019-02-06 KR KR1020207025220A patent/KR20200118103A/ko not_active Withdrawn
- 2019-02-06 AU AU2019217870A patent/AU2019217870A1/en not_active Abandoned
-
2021
- 2021-01-25 US US17/157,216 patent/US20210186984A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512904A5 (enExample) | ||
| JP2022096662A5 (enExample) | ||
| JP2023156479A5 (enExample) | ||
| JP2021530513A5 (enExample) | ||
| JP5749802B2 (ja) | 非定型抗精神病薬及びｔａａｒ１アゴニストを含む組合せ | |
| JP2021530525A5 (enExample) | ||
| JP2021515006A5 (enExample) | ||
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| CN1155409C (zh) | 用于预防和治疗动脉硬化的药物组合物 | |
| JP2022191257A5 (enExample) | ||
| RU2000114635A (ru) | Бензотиазольные ингибиторы протеинтирозинкиназ | |
| CN1311675A (zh) | 具有lgE影响性能的化合物 | |
| WO2002005797A2 (en) | Use of dopamine d2/d3 receptor agonists to treat fibromyalgia | |
| SK112001A3 (en) | Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug | |
| EP3749326A1 (en) | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides | |
| RU2010117178A (ru) | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний | |
| JP2024516826A5 (enExample) | ||
| JP2022554276A5 (enExample) | ||
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| EP3823627A1 (en) | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis | |
| JP2024507810A5 (enExample) | ||
| WO2019151470A1 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬 | |
| JP2022519274A5 (enExample) | ||
| WO2021150756A1 (en) | Inhibitors of glutathione s-transferases (gsts) and nad(p)h:quinone oxidoreductase 1 (nqo1), pharmaceutical compositions, and uses in managing cancer | |
| CN1233178A (zh) | 用于治疗性功能障碍的吡唑啉酮类 |